Nivolumab (Nivo) + Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.

Authors

Martin Reck

LungenClinic Grosshansdorf, German Center for Lung Research, Grosshansdorf, Germany

Martin Reck , Matthew David Hellmann , Luis G. Paz-Ares , Suresh S. Ramalingam , Julie R. Brahmer , Kenneth John O'Byrne , Prabhu Bhagavatheeswaran , Faith Ellen Nathan , Hossein Borghaei

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

First Author: Luis G. Paz-Ares

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.

First Author: Julie R. Brahmer

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.

First Author: Justin F. Gainor

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.

First Author: Luis G. Paz-Ares